Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:50am, Wednesday, 26'th Jun 2024
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
The Next 7 Trillion-Dollar Stocks to Buy: June 2024 Edition
07:50am, Wednesday, 26'th Jun 2024
At the time of writing, there are precisely seven trillion dollar stocks overall. One of them, Saudi Aramco, doesn't trade in US markets.
2 Reasons Why Eli Lilly's Stock Likely Hasn't Peaked
04:35am, Wednesday, 26'th Jun 2024
Eli Lilly is investing billions into additional capacity to ensure it's able to meet soaring demand for its products. Demand could accelerate even further if Mounjaro and Zepbound obtain approval for
Why Drugmaker Eli Lilly Is Partnering With ChatGPT Maker OpenAI
05:25pm, Tuesday, 25'th Jun 2024
Eli Lilly (LLY) said it is partnering with ChatGPT maker OpenAI to use artificial intelligence (AI) to develop new treatments to combat drug-resistant diseases.
Lilly partners with OpenAI to develop medicines for drug-resistant bacteria
11:11am, Tuesday, 25'th Jun 2024
Eli Lilly said on Tuesday it will collaborate with OpenAI to leverage its generative AI to develop antimicrobials that can be used to treat drug-resistant bacteria.
Is Eli Lilly (LLY) a Buy on Tirzepatide Success in Sleep Apnea?
10:05am, Tuesday, 25'th Jun 2024
Eli Lilly (LLY) files for the approval of tirzepatide to treat obstructive sleep apnea in adults with obesity in the United States. If approved, sales of the blockbuster drug will rise further.
Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria
10:00am, Tuesday, 25'th Jun 2024
INDIANAPOLIS , June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrob
From Sci-Fi Dream to Market Maze: Eli Lilly's Weight-Loss Medication Faces Hurdles
09:00am, Tuesday, 25'th Jun 2024
Founded in Indianapolis in 1876, Eli Lilly and Co. (LLY, Financial) is one of the world's top pharmaceutical companies. Its products are manufactured and distributed in more than 100 countries through
Whole Foods is promoting ‘little luxuries' as the next big food trend
08:48am, Tuesday, 25'th Jun 2024
The supermarket chain, acquired by Amazon AMZN, -1.86% in 2017, sees “little luxuries” — meaning treat-style foods packaged in treat-size portions — as a key emerging trend. Or so said Whole F
Lilly Declares Third-Quarter 2024 Dividend
11:30am, Monday, 24'th Jun 2024
INDIANAPOLIS , June 24, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2024 of $1.30 per share on outstanding common
Why a Pair of Eli Lilly Clinical Trials Sent ResMed Stock Tumbling
11:26am, Monday, 24'th Jun 2024
Shares of medical device maker ResMed (RMD) are tumbling in intraday trading Monday as markets react to a pair of Phase 3 clinical trials from drugmaker Eli Lilly (LLY) released Friday that could have
Medical-device makers ResMed and Inspire slump after Lilly's Zepbound trial shows benefits for sleep apnea
11:26am, Monday, 24'th Jun 2024
Shares of medical-device makers ResMed Inc. and Inspire Medical Systems Inc. tumbled on Monday after Eli Lilly & Co. said it has applied for regulatory approval of its weight-loss drug Zepbound to inc
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
10:05am, Monday, 24'th Jun 2024
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Again
09:23am, Monday, 24'th Jun 2024
ResMed stock and Inspire Medical Systems stock tumbled Monday after Eli Lilly said its weight-loss drug reduced sleep apnea events.
ResMed Stock Is Sinking. Blame Lilly's Zepbound Trials for Sleep Apnea.
07:49am, Monday, 24'th Jun 2024
Eli Lilly is seeking FDA approval to expand the uses for its weight-loss drug Zepbound to include sleep apnea.
